1. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102: 1884-1898. PMID:
16717343.
2. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004; 44: 520-531. PMID:
15102873.
3. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449. PMID:
16766588.
4. Park SK, Cho EJ. A Randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery. J Int Med Res 2011; 39: 399-407. PMID:
21672343.
5. Laha B, Hazra A, Mallick S. Evaluation of antiemetic effect of intravenous palonosetron versus intravenous ondansetron in laparoscopic cholecystectomy: a randomized controlled trial. Indian J Pharmacol 2013; 45: 24-29. PMID:
23543732.
6. Kim SH, Hong JY, Kim WO, Kil HK, Karm MH, Hwang JH. Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study. Korean J Anesthesiol 2013; 64: 517-523. PMID:
23814652.
7. Moon YE, Joo J, Kim JE, Lee Y. Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study. Br J Anaesth 2012; 108: 417-422. PMID:
22277663.
8. Choi DK, Chin JH, Lee EH, Lim OB, Chung CH, Ro YJ, et al. Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery. Acta Anaesthesiol Scand 2010; 54: 962-969. PMID:
20626355.
9. Park SK, Cho EJ. A randomized controlled trial of two different interventions for the prevention of postoperative nausea and vomiting: total intravenous anaesthesia using propofol and remifentanil versus prophylactic palonosetron with inhalational anaesthesia using sevoflurane-nitrous oxide. J Int Med Res 2011; 39: 1808-1815. PMID:
22117981.
10. Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg 2008; 107: 445-451. PMID:
18633022.
11. Muchatuta NA, Paech MJ. Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag 2009; 5: 21-34. PMID:
19436621.
12. Bhattacharjee DP, Dawn S, Nayak S, Roy PR, Acharya A, Dey R. A comparative study between palonosetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol 2010; 26: 480-483. PMID:
21547174.
13. Bajwa SS, Bajwa SK, Kaur J, Sharma V, Singh A, Goraya S, et al. Palonosetron: A novel approach to control postoperative nausea and vomiting in day care surgery. Saudi J Anaesth 2011; 5: 19-24. PMID:
21655011.
14. Tang J, D'Angelo R, White PF, Scuderi PE. The efficacy of RS-25259, a long-acting selective 5-HT3 receptor antagonist, for preventing postoperative nausea and vomiting after hysterectomy procedures. Anesth Analg 1998; 87: 462-467. PMID:
9706951.
15. Petru E, Andel J, Angleitner-Boubenizek L, Steger G, Bernhart M, Busch K, et al. Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wien Med Wochenschr 2008; 158: 169-173. PMID:
18421559.
16. Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am J Health Syst Pharm 2007; 64: 1209-1213. PMID:
17519464.
17. Hwang K, Shim K, Lee S, Kim H. The effect of continuous infusion of ondansetron on nausea and vomiting during intravenous patient-controlled analgesia. Korean J Anesthesiol 2004; 47: 830-833.
18. Hothersall JD, Moffat C, Connolly CN. Prolonged inhibition of 5-HT3 receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization. Br J Pharmacol 2013; 169: 1252-1262. PMID:
23581504.
19. Yamada Y, Sugiura M, Higo K, Ozeki T, Takayangagi R, Okuyama K, et al. Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol 2004; 54: 185-190. PMID:
15168080.
20. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693-700. PMID:
10485781.
21. Tarricone R, Girolami F. Economic evaluation of a new antiemetic drug - palonosetron versus ondansetron : assessment of the drug price ratio in Five European Countries. Clin Drug Investig 2005; 25: 597-608.